



BIOLABO REAGENTS
www.biolabo.fr

MANUFACTURER:
BIOLABO SAS,
Les Hautes Rives,
02160, Maizy, France

Factor VII Deficient Plasma

Immuno-depleted plasma for the determination of Factor VII activity
in citrated human plasma

REF 13307 R1 6 x 1 mL



TECHNICAL SUPPORT AND ORDERS

Tel: (33) 03 23 25 15 50

Fax: (33) 03 23 256 256

support@biolabo.fr

Latest revision: www.biolabo.fr

Made In France

I corresponds to significant modifications

INTENDED USE

I This reagent is designated for professional use in laboratory (automated or semi-automated method). It allows the quantitative determination of Factor VII activity in citrated human plasma.

This test is realized with reagents BIOLABO as follows:

REF 13702, 13704, 13712: BIO-TP LI Prothrombin Time (PT)

REF 13885, 13880 et 13881: BIO-TP Prothrombin Time (PT)

REF 13883: Owren Köller buffer dilute reference, control and patient's plasmas.

GENERALITIES (2) (4) (5) (7) (8) (10)

F.VII (proconvertin) is a Vitamin K-dependent glycoprotein composed of a single polypeptide chain. It forms with tissular factor an equimolar complex in the presence of Ca²⁺. Within this complex, F.VII can be activated into F. VIIa by Factors Xa, IXa, XIIa, and thrombin and by TF/F. VIIa complex itself.

The TFPI (Tissue Factor pathway inhibitor) inactivates the complex TF/F. VIIa.

TF/F. VIIa complex could be inhibited by antithrombin in the presence of heparin

Deficiencies in F.VII may be observed in following cases:

- Congenital deficiency of F.VII

- Acquired deficiency of F.VII associated with deficiencies of other coagulation factors:

- Intake or absorption deficiency of Vitamin K (hemorrhagic disease of the newborn, obstructive icterus, antibiotic therapy)
- Treatments with Vitamin K antagonists
- Hepatic disorders
- Fibrinolysis
- Disseminated intravascular coagulation (DIC)

- Increased levels of F.VII seem to be associated with risk factor for cardiovascular disease.

PRINCIPLE (1)

The assay consists in the measurement of the clotting time, in the presence of tissular thromboplastin and calcium, of a system in which all the factors are present in excess (supplied by Factor VII Deficient plasma) except of Factor VII which is derived from the sample being tested.

REAGENTS

R1 F-VII Deficient Plasma



Human Origin

Freeze dried citrated plasma without Factor VII (removed by selective immune- adsorption).

SAFETY CAUTIONS

- Material Safety Data Sheet is available upon request.
- Each donor unit used to manufacture this product was tested and found non-reactive for HbsAg, antibody to Hepatitis C and antibody to HIV-1/HIV-2.
- However, no test method can offer complete assurance that infectious agents are absent. All specimens or reagents from biological origin should be handled as potentially infectious, in accordance with good laboratory practices using appropriate precautions.
- Waste disposal: Respect legislation in force in the country.

I Any serious incident that has occurred in connection with the device is notified to the manufacturer and the competent authority of the Member State in which the user and/or patient is based.

REAGENTS PREPARATION

- Open the vial carefully and add exactly 1 mL of demineralized water.
- Recap and let stand for 15 minutes at room temperature.
- Before use, gently agitate to avoid the formation of foam.

STABILITY AND STORAGE

Stored away from light, well capped in the original vial at 2-8°C, when stored and used as described, reagents are stable:

Unopened:

- Until expiry date stated on the label of the kit.

Once opened:

- R1 must be reconstituted immediately,
- Once reconstituted; plasma is stable: 8 hours at 2-25°C.

SPECIMEN COLLECTION AND HANDLING (9)

Citrated Plasma: Mix freshly drawn blood (9 Volumes) with buffered tri-sodium citrate solution 3.2% (1 volume).

Centrifuge for 10 min. at 3000g and extract supernatant.

Store plasma in plastic tubes: 4h at 20-25°C,

If quickly frozen, 15 days at -20°C, 1 month at -80°C (Defrost at 37°C until complete defrosting).

Do not store at 2-8°C, because the Factor VII may be activated by the kallikrein system in this temperature range.

LIMITES (3)

Thrombin inhibitors (i.e. hirudin, argatroban ...) present in the specimen to be tested may lead to under-estimation of the Factor II activity in the specimen.

For a more comprehensive review of factors affecting this assay refer to the publication of Young D.S.

MATERIAL REQUIRED BUT NOT PROVIDED

1. Basic medical analysis laboratory equipment.
2. Automated or semi-automated coagulation analyzer

Manufacturer	Expiry date	In vitro diagnostic	Storage temperature	Dematerialized water	Biological risk
Product Reference	See Insert	Batch number	Store away from light	Sufficient for	Dilute with

CALIBRATION

- **REF** 13970: BIO CAL, reference plasma for calibration of coagulation tests

Calibration frequency depends on proper instrument functions and on the preservation of reagent.

QUALITY CONTROL

- **REF** 13971: COATROL1 Level 1
- **REF** 13972: COATROL 2 Level 2

- External quality control program.

It is recommended to control in the following cases:

- At least once a run
- At least once within 24 hours
- When changing vial of reagent
- After maintenance operations on the instrument

If control is out of range, apply following actions:

1. Prepare a fresh control serum and repeat the test
2. If control is still out of range, use a new vial of fresh calibrator
3. If control is still out of range, use a new vial of reagent and re-assay

If control is still out of range, please contact BIOLABO technical support or your local Agent.

REFERENCE INTERVALS (6)

Plasma (adult) Usually 55-170%

Each laboratory should establish its own normal ranges for the population that it serves.

PERFORMANCES CHARACTERISTICS

On automatic analyzer SOLEA 100 at 37°C:

Precision:

Intra-Assay N = 20	level 1	level 2
Mean %	99	39
S.D. %	3.0	1.0
C.V. %:	2.8	2.6

Inter-Assay N = 20	level 1	level 2
Mean %	113	59
S.D. %	5.8	3.7
C.V. %	5.1	6.2

Detection limit: equivalent to 6 % of Factor VII

Measuring Range: from 10% (QL) to 200%

Interferences on PT LI (seconds):

Turbidity	No interference up to 0.404 abs
Low Molecular weight heparin	Positive interference from 0.114 IU anti Xa
Non-fractionated Heparin	Positive interference from 0.038 IU anti Xa
Bilirubin	Positive interference from 238 µmol/L
Hemoglobin	No interference up to 209 µmol/L

Other substances may interfere with the results (see § Limits)

Onboard stability: Deficient plasma is stable 4 hours

Calibration Stability: Re-calibrate each day

Make a new calibration when changing reagent batch, if quality control results are found out of the established range and after maintenance operations.

PROCEDURE

Manual procedure on semi-automate BIO SOLEA 2, BIO SOLEA 4:

Prepare dilutions 1/10, 1/20, 1/40, 1/80 of **REF** 13970 BIO-CAL

Reference Plasma in Owren Köller buffer

Pre-incubate PT Reagent at least 15 min at 37°C and mix gently.

Measure and record the clotting time for each dilution as follows:

Reference plasma diluted 1/10 to 1/80	0,1 mL
Deficient plasma	0,1 mL
Incubate 2 minutes at 37°C.	
PT reagent (homogenized at 37°C)	0,2 mL
The automatic countdown timer will start immediately after PT reagent addition and stop when the clot is formed.	

Do the same for controls and specimens to be tested (pre-diluted 1/10 in Owren Köller buffer)

Controls and specimens (diluted 1/10)	0,1 mL
Deficient Plasma	0,1 mL
Incubate 2 minutes at 37°C.	
PT reagent (homogenized at 37°C)	0,2 mL
The automatic countdown timer will start immediately after PT reagent addition and stop when the clot is formed.	

Automated procedure: Full detailed application available on request

- Performances and stability data have been validated on SOLEA 100 and Thrombolyzer Compact X (available on request).
- With manual procedure and on other automated coagulation analyzer, performances and stability data must be validated by user.
- Other validated applications or proposal are available on request.

CALCULATION

Manual procedure:

Plot a Standard Curve using results obtained with dilutions 1/10 to 1/80 of reference plasma

Concentration % = f (Clotting Time)

Read the concentration of controls and samples reporting clotting time on the graph.

Automated and semi-automated procedure:

Patients results (seconds) will be automatically converted in % of Deficient Factor according to calibration curve.

REFERENCES

- (1) SOULIER J.P., LARRIEU M.-J.: *Sang*, **23**, 7, 549-559, 1952
- (2) CAEN J., LARRIEU M.-J., SAMAMA M.: *Paris, L'Expansion scientifique*, 153, 347, 1975
- (3) YOUNG D.S., *Effect of Drugs on Clinical laboratory Tests*, 4th Ed. (1995) p.3-254 à 3-257
- (4) CROZE M., BRIZARD C.P.: "Factor VII Padua 1" *Haemostasis*, **11**, 185-18, 1982
- (5) TAPON-BRETAUDIÈRE J.: "le facteur VII, plaque tournante de la coagulation" *Option Bio. Suppl.* 199, 1998
- (6) MARIANI G., LIBERTI G., D'ANGELO T., LO COCO L.: "Factor VII activity and antigen" *Laboratory Techniques in Thrombosis-ECAT assay procedures*. Dordrecht: Kluwer academic publishers, 99-106, 1999
- (7) GIANZILY M., SCHVED J.F.: "Les déficits constitutionnels en facteur VII" *Hématologie*, **6**, 266-271, 2000
- (8) KONIGSBERG W., KIRCHOFER D., RIEDERER M.A., NEMERSON Y.: "The TF/F.VIIa complex: clinical significance, structure-function relationships and its role in signalling and metastasis" *Thromb. Haemostasis*, **86**, 757-771, 2001
- (9) WOODHAMS B., GIRARDOT O., BLANCO M.J., COLESSE G., GOURMELIN Y.: "Stability of coagulation proteins in frozen plasma" *Blood Coag. Fibrinolysis*, **12**, 229-236, 2001
- (10) PERRY D.J.: "Review-Factor VII Deficiency" *Br. J. Haematol.*, **118**, 689-700, 2002